153 related articles for article (PubMed ID: 35911642)
1. Improvement of the inactivated SARS-CoV-2 vaccine potency through formulation in alum/naloxone adjuvant; Robust T cell and anti-RBD IgG responses.
Haghighi M; Khorasani A; Karimi P; Mahdavi M
Iran J Basic Med Sci; 2022 May; 25(5):554-561. PubMed ID: 35911642
[TBL] [Abstract][Full Text] [Related]
2. Different Formulations of Inactivated SARS-CoV-2 Vaccine Candidates in Human Compatible Adjuvants: Potency Studies in Mice Showed Different Platforms of Immune Responses.
Haghighi M; Khorasani A; Karimi P; Keshavarz R; Mahdavi M
Viral Immunol; 2022 Dec; 35(10):663-672. PubMed ID: 36534465
[TBL] [Abstract][Full Text] [Related]
3. Formulation of a recombinant HIV-1 polytope candidate vaccine with naloxone/alum mixture: induction of multi-cytokine responses with a higher regulatory mechanism.
Fathi M; Nezamzadeh R; Abdollahpour-Alitappeh M; Yazdi MH; Khoramabadi N; Mahdavi M
APMIS; 2021 Aug; 129(8):480-488. PubMed ID: 33539574
[TBL] [Abstract][Full Text] [Related]
4. Montanide ISA-720 and Naloxone in HBsAg Vaccine Formulation: Cytokine Profiling and Monitoring of Long-Lasting Humoral Immune Responses.
Mirzaee M; Haghighat S; Golkaran B; Asgarhalvaei F; Mirzaee R; Taghizadeh M; Savoji MA; Esfandiari B; Mahdavi M
Biomed Environ Sci; 2022 Sep; 35(9):792-803. PubMed ID: 36189994
[TBL] [Abstract][Full Text] [Related]
5. A Survey on the Adjuvant Role of Naloxone Alone or Combined with Alum in Vaccination Against Fasciolosis in BALB/c Mice.
Azizi H; Mirzaeei H; Bagheri A; Bazi A; Khamesipour A; Yaghoobi H; Mirzapour A; Khatami M; Elikaee S
Acta Parasitol; 2019 Jun; 64(2):236-245. PubMed ID: 30788648
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of human papilloma vaccine candidate using naloxone/alum mixture as an adjuvant: increasing immunogenicity of HPV-16E7d vaccine.
Yasaghi M; Mahdavi M
Iran J Basic Med Sci; 2016 Sep; 19(9):1003-1009. PubMed ID: 27803788
[TBL] [Abstract][Full Text] [Related]
7. Naloxone/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responses.
Velashjerdi Farahani S; Reza Aghasadeghi M; Memarnejadian A; Faezi S; Shahosseini Z; Mahdavi M
Pathog Glob Health; 2016 Mar; 110(2):39-47. PubMed ID: 26403975
[TBL] [Abstract][Full Text] [Related]
8. Nanoadjuvants Produced by Advanced Nanochelating Technology in the Inactivated-Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine Formulation: Preliminary Results on Cytokines and IgG Responses.
Kalanaky S; Fakharzadeh S; Karimi P; Hafizi M; Jamaati H; Hassanzadeh SM; Khorasani A; Mahdavi M; Nazaran MH
Viral Immunol; 2023; 36(6):409-423. PubMed ID: 37506342
[TBL] [Abstract][Full Text] [Related]
9. Naloxone and alum synergistically augment adjuvant activities of each other in a mouse vaccine model of Salmonella typhimurium infection.
Jazani NH; Parsania S; Sohrabpour M; Mazloomi E; Karimzad M; Shahabi S
Immunobiology; 2011 Jun; 216(6):744-51. PubMed ID: 21093956
[TBL] [Abstract][Full Text] [Related]
10. PPD in HBsAg vaccine formulation suppressed IFN-γ and IL-4 cytokine responses and induced long-lived humoral immune responses: Results from 220-day monitoring of specific IgG responses.
Mirzaee R; Nemati F; Mirzaee M; Golkaran B; Khorasani A; Rashedi N; Asgarhalvaei F; Savoji MA; Mahdavi M
Iran J Basic Med Sci; 2022 Nov; 25(11):1326-1333. PubMed ID: 36474577
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of SARS-CoV-2 Trimeric Spike Protein Associated to Poly(I:C) Plus Alum.
Dos-Santos JS; Firmino-Cruz L; da Fonseca-Martins AM; Oliveira-Maciel D; Perez GG; Roncaglia-Pereira VA; Dumard CH; Guedes-da-Silva FH; Santos ACV; Leandro MDS; Ferreira JRM; Guimarães-Pinto K; Conde L; Rodrigues DAS; Silva MVM; Alvim RGF; Lima TM; Marsili FF; Abreu DPB; Ferreira OC; Mohana Borges RDS; Tanuri A; Souza TML; Rossi-Bergmann B; Vale AM; Silva JL; de Oliveira AC; Filardy AD; Gomes AMO; de Matos Guedes HL
Front Immunol; 2022; 13():884760. PubMed ID: 35844561
[TBL] [Abstract][Full Text] [Related]
12. A novel adjuvant, a mixture of alum and the general opioid antagonist naloxone, elicits both humoral and cellular immune responses for heat-killed Salmonella typhimurium vaccine.
Jazani NH; Sohrabpour M; Mazloomi E; Shahabi S
FEMS Immunol Med Microbiol; 2011 Feb; 61(1):54-62. PubMed ID: 21054579
[TBL] [Abstract][Full Text] [Related]
13. The Immunogenicity of CpG, MF59-like, and Alum Adjuvant Delta Strain Inactivated SARS-CoV-2 Vaccines in Mice.
Xu K; Li J; Lu X; Ge X; Wang K; Wang J; Qiao Z; Quan Y; Li C
Vaccines (Basel); 2024 Jan; 12(1):. PubMed ID: 38250873
[TBL] [Abstract][Full Text] [Related]
14. Formulation of Recombinant H1N1 Hemagglutinin in MF59 and Alum Adjuvants: A Comparison of the Vaccines Potency and Efficacy in BALB/C Mice.
Sepasi A; Ghafourian M; Taghizadeh M; Mahdavi M
Viral Immunol; 2023; 36(6):401-408. PubMed ID: 37504965
[TBL] [Abstract][Full Text] [Related]
15. A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice.
Coria LM; Saposnik LM; Pueblas Castro C; Castro EF; Bruno LA; Stone WB; Pérez PS; Darriba ML; Chemes LB; Alcain J; Mazzitelli I; Varese A; Salvatori M; Auguste AJ; Álvarez DE; Pasquevich KA; Cassataro J
Front Immunol; 2022; 13():844837. PubMed ID: 35296091
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity Studies of Plant-Produced SARS-CoV-2 Receptor Binding Domain-Based Subunit Vaccine Candidate with Different Adjuvant Formulations.
Siriwattananon K; Manopwisedjaroen S; Shanmugaraj B; Prompetchara E; Ketloy C; Buranapraditkun S; Tharakhet K; Kaewpang P; Ruxrungtham K; Thitithanyanont A; Phoolcharoen W
Vaccines (Basel); 2021 Jul; 9(7):. PubMed ID: 34358160
[TBL] [Abstract][Full Text] [Related]
17. The immunogenicity of Alum+CpG adjuvant SARS-CoV-2 inactivated vaccine in mice.
Yang J; Li B; Yang D; Wu J; Yang A; Wang W; Lin F; Wan X; Li Y; Chen Z; Lv S; Pang D; Liao W; Meng S; Lu J; Guo J; Wang Z; Shen S
Vaccine; 2023 Sep; 41(41):6064-6071. PubMed ID: 37640568
[TBL] [Abstract][Full Text] [Related]
18. Improvement of hepatitis B vaccine to induce IFN-γ cytokine response: A new formulation.
Rahimkhani A; Haghighat S; Noorbazargan H; Mahdavi M
Microb Pathog; 2021 Nov; 160():105184. PubMed ID: 34508828
[TBL] [Abstract][Full Text] [Related]
19. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
20. Mixture of Alum--Naloxone and Alum--Naltrexone as a novel adjuvant elicits immune responses for Toxoplasma gondii lysate antigen in BALB /c mice.
Khorshidvand Z; Shahabi S; Mohamadzade H; Daryani A; Hazrati Tappeh K
Exp Parasitol; 2016 Mar; 162():28-34. PubMed ID: 26773164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
